Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
3.140
+0.020 (0.64%)
May 5, 2026, 4:00 PM EDT - Market closed
Evotec SE Revenue
In the year 2025, Evotec SE had annual revenue of 788.37M EUR, down -1.08%. Evotec SE had revenue of 253.27M in the quarter ending December 31, 2025, with 14.49% growth.
Revenue (ttm)
788.37M EUR
Revenue Growth
-1.08%
P/S Ratio
1.20
Revenue / Employee
176,488 EUR
Employees
4,467
Market Cap
1.11B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 788.37M | -8.59M | -1.08% |
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 111.64M | 42.33% |
| Dec 31, 2017 | 263.77M | 99.26M | 60.34% |
| Dec 31, 2016 | 164.51M | 36.83M | 28.85% |
| Dec 31, 2015 | 127.68M | 38.18M | 42.66% |
| Dec 31, 2014 | 89.50M | 3.56M | 4.14% |
| Dec 31, 2013 | 85.94M | -1.33M | -1.52% |
| Dec 31, 2012 | 87.27M | 7.14M | 8.91% |
| Dec 31, 2011 | 80.13M | 24.87M | 45.00% |
| Dec 31, 2010 | 55.26M | 12.58M | 29.47% |
| Dec 31, 2009 | 42.68M | 3.07M | 7.75% |
| Dec 31, 2008 | 39.61M | -14.77M | -27.16% |
| Dec 31, 2007 | 54.38M | -30.30M | -35.78% |
| Dec 31, 2006 | 84.68M | 4.90M | 6.14% |
| Dec 31, 2005 | 79.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.25B |
| Tilray Brands | 858.28M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 734.86M |
| Amphastar Pharmaceuticals | 719.89M |
| Alvotech | 588.90M |
| Esperion Therapeutics | 403.14M |
| Harrow | 272.30M |
EVO News
- 1 day ago - Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall - Accesswire
- 5 days ago - Evotec Receives Grants to Advance Tuberculosis Treatment - Accesswire
- 5 days ago - Evotec Announces New Nomination to Board of Directors - Accesswire
- 6 days ago - Evotec SE to Announce First Quarter 2026 Results on May 6, 2026 - Accesswire
- 11 days ago - Evotec Announces Chief Financial Officer Transition - Accesswire
- 20 days ago - Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer - Accesswire
- 4 weeks ago - Evotec vows to further engage with investor MAK, who demanded change - Reuters
- 4 weeks ago - Evotec Nominates Dieter Weinand as Supervisory Board Chairman - Accesswire